Comparison of immunogenicity, efficacy and transcriptome changes of inactivated rabies virus vaccine with different adjuvants

Shi, Wei; Kou, Yiming; Xiao, Jing; Zhang, Lijuan; Gao, Feng; Kong, Wei; Su, Weiheng; Jiang, Chunlai; Zhang, Yong

doi:10.1016/j.vaccine.2018.07.006

Cited by 23 publications

(13 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, only a few reports have been found on the use of the transcriptome to analyze the effects of vaccine adjuvants. Recently, transcriptome analysis was used to study the role of adjuvants in rabies vaccine immunization and found that there were significant differences in gene expression between the mice immunized with different type of adjuvants, except for two aluminum adjuvant vaccines, which induced similar gene expression [56]. In the present study, more significantly DEGs were found in the SO-VE-GS group than in the ISA 206 group by RNA-sequence analysis ( Figure 6A).…”

Section: Discussionsupporting

confidence: 56%

Early IgG Response to Foot and Mouth Disease Vaccine Formulated with a Vegetable Oil Adjuvant

et al. 2019

View full text Add to dashboard Cite

The present study evaluated soybean oil (SO) containing vitamin E (VE) and ginseng saponins (GS) (SO-VE-GS) for their adjuvant effect on foot-and-mouth disease (FMD) vaccine. Since mineral oil ISA 206 is a common adjuvant used in the FMD vaccine, it was used as a control adjuvant in this study. VE and GS were found to have a synergistic adjuvant effect. When mice were immunized with the FMD vaccine emulsified in SO with VE and GS, significantly higher serum IgG, IgG1, and IgG2a were found than VE and GS used alone. SO-VE-GS and ISA 206 behaved differently in adjuvant activities. When mice were immunized with the FMD vaccine adjuvanted with SO-VE-GS, significantly higher and earlier production of serum IgG was found than that adjuvanted with ISA 206. Although both adjuvants significantly increased the number of bone marrow plasma cells, a stimulation index of lymphocytes (SI) as well as the production of IL-4 and IL-6, SO-VE-GS promoted significantly higher SI and the ratio of CD4+/CD8+ T cells with production of increased IFN-γ and decreased TGF-β1 as compared with the ISA 206 group. The data suggested that SO-VE-GS activated Th1/Th2 immune responses. Transcriptome analysis of splenocytes showed that differentially expressed genes (DEGs), immune-related gene ontology (GO) terms, and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways were significantly enriched in the SO-VE-GS group. Therefore, the potent adjuvant effect of SO-VE-GS on the FMD vaccine may be attributed to the immune-related gene profile expressed in lymphocytes. Due to its plant origin and due to being much cheaper than imported mineral oil ISA 206, SO-VE-GS deserves further study in relation to vaccines used in food animals.

show abstract

Section: Discussionsupporting

confidence: 56%

Early IgG Response to Foot and Mouth Disease Vaccine Formulated with a Vegetable Oil Adjuvant

et al. 2019

View full text Add to dashboard Cite

show abstract

“…MF59, AS03, and AS02 are squalene-based oil-in-water emulsions with 150–160 nm particles. Squalene-based adjuvants were prepared as previously described, and all polydispersity indexes of these adjuvants are less than 0.15 ( 38 , 39 ). To ensure consistent adjuvant dose, each mouse was given an adjuvant totally containing 2.15 mg squalene at immunization.…”

Section: Methodsmentioning

confidence: 99%

“…Total RNA was isolated with TRIzol (Invitrogen, United States). Transcriptome sequencing and differential gene expression analysis were performed as previously described ( 38 ). RNA degradation and contamination were assayed on 1% agarose gels, and RNA purity was verified using a NanoPhotometer spectrophotometer (IMPLEN, US).…”

Section: Methodsmentioning

confidence: 99%

Respiratory Syncytial Virus F Subunit Vaccine With AS02 Adjuvant Elicits Balanced, Robust Humoral and Cellular Immunity in BALB/c Mice

et al. 2020

Self Cite

View full text Add to dashboard Cite

Respiratory syncytial virus (RSV) is a leading cause of lower respiratory illness, particularly in infants, the elderly, and immunocompromised adults. There is no licensed commercial vaccine against RSV. Importantly, formalin-inactivated RSV vaccines mediate enhanced respiratory disease. RSV fusion (F) protein with pre-fusion conformation is a promising candidate subunit vaccine. However, some problems remain to be solved, such as low immunogenicity and humoral immunity bias. Adjuvants can effectively enhance and adjust vaccine immune responses. In this study, we formulated pre-fusion RSV-F protein with the adjuvants, Alhydrogel, MF59, AS03, AS02, and glycol chitosan (GCS). We then conducted head-to-head comparisons of vaccine-induced immune responses in BALB/c mice. All adjuvanted vaccines enhanced antigen-specific and neutralizing antibody titers and viral clearance and gave an order of adjuvant activity: AS02 > AS03, MF59 > GCS, and Alhydrogel. Among them, AS02 elicited the highest antibody expression, which persisted until week 18. Moreover, AS02 significantly enhanced Th1 type immune response in immunized mice. Mice in the AS02 group also showed faster recovery from viral attacks in challenge tests. Further transcriptome analysis revealed that AS02 regulates immune balance by activating TLR-4 and promotes Th1-type immune responses. These results suggest that AS02 may be an excellent candidate adjuvant for RSV-F subunit vaccines. This study also provides valuable information regarding the effect of other adjuvants on immune responses of RSV-F subunit vaccines.

show abstract

“…For example, compared with traditional aluminum adjuvants, nano-aluminum adjuvants can significantly enhance the immune effect of Bacillus anthracis protective antigen and can induce a lower proinflammatory response at the injection site [18]. In an activated rabies virus vaccine, nano-aluminum adjuvants showed better immune enhancement effects than traditional aluminum adjuvants and a few new adjuvants (e.g., AS02, AS03, MF59) [19].…”

Section: Nanonizationof Aluminum Adjuvantsmentioning

confidence: 99%

Better Adjuvants for Better Vaccines: Progress in Adjuvant Delivery Systems, Modifications, and Adjuvant–Antigen Codelivery

Wang

2020

Vaccines

113

View full text Add to dashboard Cite

Traditional aluminum adjuvants can trigger strong humoral immunity but weak cellular immunity, limiting their application in some vaccines. Currently, various immunomodulators and delivery carriers are used as adjuvants, and the mechanisms of action of some of these adjuvants are clear. However, customizing targets of adjuvant action (cellular or humoral immunity) and action intensity (enhancement or inhibition) according to different antigens selected is time-consuming. Here, we review the adjuvant effects of some delivery systems and immune stimulants. In addition, to improve the safety, effectiveness, and accessibility of adjuvants, new trends in adjuvant development and their modification strategies are discussed.

show abstract

Comparison of immunogenicity, efficacy and transcriptome changes of inactivated rabies virus vaccine with different adjuvants

Cited by 23 publications

References 49 publications

Early IgG Response to Foot and Mouth Disease Vaccine Formulated with a Vegetable Oil Adjuvant

Early IgG Response to Foot and Mouth Disease Vaccine Formulated with a Vegetable Oil Adjuvant

Respiratory Syncytial Virus F Subunit Vaccine With AS02 Adjuvant Elicits Balanced, Robust Humoral and Cellular Immunity in BALB/c Mice

Better Adjuvants for Better Vaccines: Progress in Adjuvant Delivery Systems, Modifications, and Adjuvant–Antigen Codelivery

Contact Info

Product

Resources

About